Today: 21 November 2025
Subscribe
Browse Category

Investment Analysis News 30 October 2025 - 31 October 2025

Datavault AI (DVLT) Skyrockets 800% on Bitcoin Deal and IBM Partnership – Can the AI Stock Rally Last?

Datavault AI (DVLT) Skyrockets 800% on Bitcoin Deal and IBM Partnership – Can the AI Stock Rally Last?

Company Overview & Stock Performance Datavault AI Inc. (NASDAQ: DVLT) is a micro-cap tech company that specializes in turning data into a valuable asset. The firm’s cloud-based platform uses AI and blockchain to visualize, value, and monetize data across industries ir.datavaultsite.com. (For example, Datavault enables creation of “digital twins” of real-world assets and secure data exchanges to trade information.) Originally a wireless audio tech company, DVLT rebranded and pivoted to the Web3 data monetization space, riding the wave of investor enthusiasm for anything AI-related. This year, Datavault’s stock has been on a roller-coaster rally. In late September 2025, DVLT was
31 October 2025
 ·  ·  ·  ·  ·  · 
Alphabet (Google) GOOGL stock: What to Know Before Markets Open on October 20, 2025

Alphabet (Google) Stock Skyrockets on AI & Cloud Boom – Could $300 Be Next?

Stock Performance and Market Snapshot Alphabet’s stock has been on a tear. After closing around $265 on Oct 27, 2025, Class A shares (GOOGL) spiked following the Q3 report and trade near $280 as of Oct 31 ts2.tech. Over the past year the stock is up well over 30%, reflecting optimism around AI and digital ads. Trading volumes have been robust amid volatility in the broader tech sector. Importantly, Alphabet is now one of only a few companies (with Apple, Microsoft) above the $3 trillion market cap threshold ts2.tech, underscoring its massive scale. Recent moves have set new record highs: for
31 October 2025
 ·  ·  ·  ·  · 
Luminar’s LiDAR Rollercoaster: LAZR Stock Soars on Buyout Buzz, Crashes on Cash Crunch – October 2025 Update

Luminar’s LiDAR Rollercoaster: LAZR Stock Soars on Buyout Buzz, Crashes on Cash Crunch – October 2025 Update

Latest News: Buyout Buzz vs. Cash Crunch Late October brought whiplash for Luminar investors. On Oct. 25, 2025, Luminar’s stock skyrocketed ~31% in a single session, hitting an intraday high around $2.28 ts2.tech ts2.tech. This surge was fueled by two factors: a broad tech rally (markets jumped on cooling inflation and AI optimism) and speculation about a buyout led by Luminar’s founder. Media reports and an SEC filing revealed that Austin Russell – Luminar’s 28-year-old founder who was ousted as CEO in May – had proposed a deal to acquire all outstanding Class A shares through his new venture, Russell AI
31 October 2025
 ·  ·  ·  ·  · 
Stocks Surge as Trump Eases China Tariff Threats – Fed Rate-Cut Hopes Ignite Rally

VOO ETF Rockets to Record Highs After Fed Rate Cut – Tech Surge Powers Rally, Analysts Weigh In

VOO tracks the S&P 500 Index (500 large-cap U.S. stocks) and has roughly the same YTD return as its peers SPY and IVV (around 16% finviz.com finviz.com). By contrast, the tech-heavy Nasdaq ETF QQQ is up ~22.5% YTD finviz.com, reflecting the AI-driven rally. An ETF flow report notes that VOO’s ~$625 price (Oct 10) reflects the S&P 500’s ~15% gain in 2025 ts2.tech. Importantly, VOO has led all U.S. ETFs in inflows year-to-date (over $80 B in 2025) as investors favor its ultra-low 0.03% fee ts2.tech ainvest.com. Recent Performance and Trends Through October 2025, VOO has logged steady gains. It’s roughly 16.0%
31 October 2025
 ·  ·  ·  · 
Quantum Rocket or Bubble? RGTI’s Stunning Surge Explained—And How It Stacks Up to IonQ, D‑Wave, and QUBT

Rigetti (RGTI) Quantum Stock Skyrockets 5,000% – October 2025 News, Price & Analyst Report

Key Facts: Rigetti Computing (NASDAQ: RGTI) has been on a historic tear in 2025, rising roughly 50× from penny-stock levels to intraday highs near $56 ts2.tech. By Oct. 30, 2025 it closed around $42.52 (up 7.9% on the day) stockanalysis.com. Its YTD gain (~2,800–5,000%) far eclipses peers like IonQ (+270%) or D-Wave (up thousands of %) ts2.tech. Recent catalysts include major deals and tech wins: in late Sept 2025 Rigetti (with Dutch partner QphoX) won a $5.8 M U.S. Air Force quantum-networking contract and concurrently booked ~$5.7 M in orders for two new 9-qubit Novera™ systems ts2.tech rigetti.com. In late Oct, Rigetti
31 October 2025
 ·  ·  ·  ·  · 
Cloudflare (NET) Stock Soars on Q3 Earnings Beat and AI-Security Partnerships – Analysts Predict Further Gains

Cloudflare (NET) Stock Soars on Q3 Earnings Beat and AI-Security Partnerships – Analysts Predict Further Gains

Stock Performance and Market Reaction Over the past week Cloudflare’s stock has hovered near record highs, driven by broader tech momentum and anticipation of its earnings beat. Investing.com data show NET closed Oct 30 at $222.94, down ~1.95% on the day investing.com. This followed a +1.51% gain on Oct 29 investing.com. On Oct 30 the stock traded as high as ~$226.90 before profit-taking. Crucially, after the market close on Oct 30, Cloudflare’s Q3 results triggered a surge: in after-hours trading NET touched a fresh all-time high around $230.31 watcher.guru. Overall, NET is up roughly 95% year-to-date (about 111% since April)
30 October 2025
 ·  ·  ·  · 
EMCOR Group (EME) Delivers Record Q3 – So Why Are Shares Crashing?

EMCOR Group (EME) Delivers Record Q3 – So Why Are Shares Crashing?

EMCOR’s Oct 30 report painted an overwhelmingly positive picture: “We had an outstanding third quarter,” CEO Tony Guzzi told analysts businesswire.com, noting 16.4% revenue growth and an all-time high backlog. Net income was $295.4M (diluted EPS $6.57) businesswire.com, well above last year’s $270.3M ($5.80 EPS). In fact, EMCOR narrowly beat the street’s EPS consensus (~$6.53) nasdaq.com – though it fell slightly below a higher Zacks estimate of $6.65 timesunion.com. The full-year outlook was boosted: revenues now expected ~$16.75 B (vs prior ~$16.65B) with EPS at least $25.00 businesswire.com nasdaq.com. Guzzi highlighted that performance obligations (“booked” future work) jumped to $12.61B businesswire.com,
30 October 2025
 ·  ·  ·  ·  · 
eBay Stock Soars on Earnings Beat, Stumbles on Weak Holiday Outlook

eBay Stock Soars on Earnings Beat, Stumbles on Weak Holiday Outlook

Stock Price Rallies, Then Pulls Back eBay’s stock price has enjoyed a strong 2025 rally, nearly doubling from mid-2024 levels ts2.tech. By late October 2025, shares traded just shy of a 52-week high (~$101) after climbing steadily on optimism about the company’s strategy. On October 29, EBAY hit an intraday high above $101 and closed around $99.33 ts2.tech, marking roughly a 60% year-to-date gain – far outpacing the Nasdaq-100’s ~19% YTD rise ts2.tech. Investors have been enthused by eBay’s focus on niche collectibles and AI-powered tools. As Bloomberg observes, eBay is “trying to embrace increased demand for used and refurbished
30 October 2025
 ·  ·  ·  ·  · 
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

BMY Stock Bounces After Earnings – Recent Performance Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year low of $42.96 (closing at $42.99) marketbeat.com. That put BMY down roughly 18–19% year-to-date, significantly underperforming the pharma sector (which was roughly flat to slightly up over the same period) nasdaq.com. By comparison, an index of large pharmaceutical stocks was
30 October 2025
 ·  ·  ·  · 
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Inc. (Nasdaq: BIIB) is a leading neuroscience biotech known for multiple sclerosis and rare-disease therapies ts2.tech. On Oct. 30, 2025 the stock dipped after a mixed earnings release. The company beat Q3 expectations – adjusted EPS $4.81 vs. $3.88 est and $2.53 B revenue vs. $2.34 B est ng.investing.com – but lowered its full-year outlook. Biogen now expects 2025 non-GAAP EPS of $14.50–$15.00 (previously $15.50–16.00), citing an anticipated ~$1.25 per-share charge in Q4 for recent R&D deals reuters.com reuters.com. CEO Chris Viehbacher spun the quarter positively, noting “we delivered another quarter of strong financial performance driven by … momentum in our
30 October 2025
 ·  ·  ·  · 
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

CI Stock Price and Recent Trend Cigna’s stock has pulled back modestly in late October after a strong run earlier in the year. According to market data, CI closed at $299.12 on Oct 29, 2025, down about 3% from the previous close stockanalysis.com. The dip followed weakness in broader managed-care stocks amid concerns about healthcare costs and policy. In pre-market trading Oct 30, CI rebounded to about $303 (up ~1.3%) reuters.com. Over the past year, CI shares have traded between roughly $257 and $350 stockanalysis.com, reflecting volatility in the insurance sector. Despite the pullback, Cigna’s valuation metrics remain attractive: at
30 October 2025
 ·  ·  ·  · 
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck’s stock price dipped on Oct 30, 2025 even as it delivered a strong third-quarter report. The company posted $17.28 B in Q3 sales and $2.58 adjusted EPS – above analyst forecasts marketscreener.com. Sales of Keytruda, its blockbuster cancer drug, grew about 10% (to $8.1 B) marketscreener.com, offsetting a drop in Gardasil vaccine revenue. Despite the beat, Merck narrowed its 2025 sales outlook (now $64.5–65.0 B) while slightly raising profit guidance marketscreener.com, a cautious stance that likely weighed on the share price. Pipeline and Drug Approvals Drive Hopes Beyond the quarterly numbers, recent product news is energizing Merck’s outlook. In September 2025 the
30 October 2025
 ·  ·  ·  ·  · 
1 … 15 16 17 18 19 … 31
Go toTop